We thank Dr. Dewar1 for her interest in our CMAJ article.2 We considered a broad workup for contributory and aggravating causes and conducted a complete assessment during the clinical encounter. However, this could not all be captured within the article’s word limit. For clarification, we provide further details.
During the early months of the coronavirus disease 2019 (COVID-19) pandemic, our patient was assessed in-person in the emergency department, enabling a thorough history and a complete physical examination. Our patient had no history of nicotine or psychostimulant consumption. In addition, her review of systems was negative, including for those of autoimmune disorders and malignant disease (i.e., no fever, night sweats, weight changes, oral or genital ulcerations, photosensitivity, arthritis, arthralgias, morning stiffness, myalgias, muscle weakness, sicca symptoms or other cutaneous eruptions). The patient also did not have a family history of known autoimmune conditions. Other than the acral lesions described in our article, her physical examination was unremarkable. In particular, she had a normal body habitus without clinical signs of anorexia nervosa, no other cutaneous findings such as oral ulcerations or photo-distributed lesions, and normal nail capillaroscopy. We did not pursue a musculoskeletal examination given the lack of symptoms.
We completed a thorough panel of investigations to rule out systemic causes of chilblains. We did not conduct imaging investigations given the absence of respiratory symptoms before, during and after clinical encounter, and because chest imaging is not recommended to diagnose COVID-19 in patients with mild features.3 In addition, imaging would not have altered the cutaneous management.
We agree that a skin biopsy is not always required for diagnosis of chilblains because the findings are not pathognomonic but rather supportive of a clinical diagnosis. Our patient presented near the beginning of the pandemic when little was known about severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related chilblains. There have been reports of classic chilblains histology associated with SARS-CoV-2 infection, as well as superficial and deep lichenoid lymphocytic changes with basal vacuolar changes;4,5 microthrombi have also been described.6,7 A biopsy was completed to assess for microthrombi and to rule out vaso-occlusive pathology.
Idiopathic chilblains remain a diagnosis of exclusion. Patients presenting with chilblains should be appropriately examined and investigated to rule out secondary systemic causes. Our patient’s thorough history, physical examination and subsequent workup did not support any underlying disorder. Chilblains related to SARS-CoV-2 was favoured because of negative secondary workup, absence of cool/damp exposure and positive results for serology testing. The understanding of SARS-CoV-2-related chilblains and its pathogenesis will continue to evolve in the coming months.
Footnotes
Competing interests: None declared.